| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Perspective Therapeutics (AMEX:CATX) is preparing to release its quarterly earnings on Wednesday, 2025-08-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Perspective Therapeutics to report an earnings per share (EPS) of $-0.29.
The market awaits Perspective Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Last quarter the company beat EPS by $0.02, which was followed by a 1.59% increase in the share price the next day.
Here's a look at Perspective Therapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.27 | -0.26 | -0.21 | -0.21 |
| EPS Actual | -0.25 | -0.60 | -0.21 | -0.17 |
| Price Change % | 2.0% | 1.0% | -7.000000000000001% | 6.0% |
Shares of Perspective Therapeutics were trading at $3.72 as of August 11. Over the last 52-week period, shares are down 70.61%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CATX
